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Abstract
It remains unknown whether application of nasal high flow (NHF) is
effective after liberation from non-invasive ventilation (NIV). This study
was aimed at investigating the effect of NHF in patients ready for
weaning from NIV.
With institutional ethic committee approval, patients receiving NIV due
to hypoxemic respiratory failure for more than 24 hours were enrolled.
After passing the weaning criteria with continuous positive airway
pressure (CPAP) mode [fraction of inspiratory oxygen (FIO2) ≦0.5,
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positive end expiratory pressure (PEEP) 4 cmH2O], patients received
NHF (Flow 50 L/min, FIO2 ≦0.5) immediately after liberation from NIV.
Before the initiation of the study, eight sequential patients who received
oxygen via face mask after NIV treatment, served as the historical
control. Respiratory parameters [partial pressure of arterial oxygen
(PaO2) to FIO2 ratio (P/F ratio), respiratory rate (RR)] 1 hour after
liberation from NIV were evaluated with those during NIV as the primary
outcome. The frequency of rescue NIV therapy, intubation, and
respiratory failure were also recorded.
Nine eligible patients received NHF therapy after liberation from NIV.
P/F ratio and RR did not change significantly compared with those
during NIV (231 ± 43.6 versus 250.7 ± 34.2 mmHg, 20.8 ± 2.3 versus 21
± 1.6 /min), while P/F ratio decreased significantly in the historical
control group (194.3 ± 20.1 versus 255.9 ± 58.1 mmHg, p=0.013). Rescue
NIV therapy, intubation, and respiratory failure never occurred in the
NFH group, although two patients received NIV rescue therapy, of whom
one was intubated in the historical control.
NHF after liberation from NIV might be effective in patients recovering
from hypoxemic respiratory failure.
Registration number: UMIN000014133 (UMIN-CTR)
Key words: hypoxemic respiratory failure, weaning, non-invasive
ventilation, nasal high flow oxygen therapy, weaning failure, rescue
therapy
Introduction
Non-invasive ventilation (NIV) has been recognized as effective therapy
in improving gas exchange while reducing dyspnea in patients with not
only hypercapnic but also hypoxemic respiratory failure. (1,2) Previous
studies have shown that NIV can treat respiratory failure without
invasive mechanical ventilation, (3) avert the need for re-intubation after
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extubation in patients with risk factors, (4) and facilitate weaning from
invasive ventilator support in medical patients predominantly with
chronic obstructive pulmonary disease (COPD). (5) Contrary to these
beneficial effects of NIV, there are some concerns regarding difficulties of
NIV management. NIV prevents early mobilization, causes gastric
distension, inhibits communication and oral intake, is poorly tolerated in
some patients, and associated with facial injuries especially when the
duration of NIV management is prolonged. (6) Thus, liberation from NIV
as early as possible is one of the major goals in managing respiratory
failure under NIV application. However, some patients develop
respiratory failure after weaning from NIV to oxygen face mask even
though the final positive end expiratory pressure (PEEP) level is at a
minimum, which suggest that bridging therapy from NIV to face mask
might be necessary for some patients.
Nasal high flow (NHF) oxygen therapy, which is well established in
neonates and has recently been used in adult populations, (7) can deliver
high flow humidified, blended air and oxygen up to 60 L/min via wide-
bore nasal cannula at a prescribed fraction of inspiratory oxygen (FIO2).
(8) Given that the beneficial effects of NHF, such as improving
oxygenation, reducing work of breathing, and facilitating secretion
clearance, have been reported in recent studies, (9-11) NHF might be
useful to wean patients from NIV to oxygen face mask efficiently and
safely. However, there are few studies which have examined the effects of
NHF on respiratory parameters through comparison with those of NIV,
and evaluated the efficacy of NHF after liberation from NIV.
In this study, we examined the effect of NHF application after liberation
from NIV management, compared with the historical control group in
which patients received oxygen face mask after weaning from NIV.
Materials and Methods
This prospective, observational study was conducted in our 8-bed
intensive care unit (ICU) of Kawasaki Municipal Hospital in Japan to
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investigate the effect of NHF on respiratory parameters in patients
weaned from NIV during the period from September 2012 to March
2013. The protocol was approved by the regional ethics committee, which
waived informed consent, since this study was observational in nature,
and all procedures were established as routine practices in our ICU.
Patients receiving NIV through full face mask for more than 24 hours
due to hypoxemic respiratory failure were screened for eligibility in this
study, and all patients who met all the following inclusion criteria were
enrolled in this study: (1) partial pressure of arterial oxygen (PaO2) to
FIO2 ratio (P/F ratio) more than 200 mmHg with positive end expiratory
pressure (PEEP) of 5 cm of water or less; (2) respiratory rate (RR) less
than 30 breathes per min (bpm) with pressure support of 5 cm of water
or less; (3) pH of blood gas analysis more than 7.35; (4) hemodynamic
stability without vasopressor therapy; (5) adequate conscious level and
cough reflex; (6) no agitation. Patients younger than 18 years old or with
Glasgow Coma Scale less than 14 or with body mass index (BMI) more
than 30 were excluded from this study.
As a historical control group, eight consecutive patients under NIV
management because of hypoxemic respiratory failure, who were ready
for weaning from NIV, were chosen before the initiation of this study.
They received oxygen face mask therapy after liberation from NIV as
standard care in our ICU.
NIV was delivered for all patients using the same device (BiPAP Vision,
Respironics, USA). In patients who met all the inclusion criteria, the
respiratory setting of NIV was changed to continuous positive airway
pressure (CPAP) mode with PEEP of 4 cmH2O and FIO2 equal to or less
than 0.5. NIV was interrupted, and humidified high-flow oxygen via NHF
system (Optiflow with MR880 humidifier, Fisher & Paykel Healthcare,
Auckland, New Zealand) was delivered through a wide-bore nasal
cannula at the following setting; gas flow 50 l/min and FIO2 equal to or
less than 0.5, if patients passed all the following criteria, described
below, 1hour after changing the respiratory setting of NIV: (1) P/F ratio
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more than 200 mmHg; (2) RR less than 30 bpm; (3) pH of blood gas
analysis more than 7.35; (4) hemodynamic stability without vasopressor
therapy; (5) adequate conscious level and cough reflex; (6) no agitation.
The setting of NHF was not changed until 1hour after the initiation of
NHF therapy if patients could maintain oxygen saturation by pulse
oximetry (SpO2) more than 92% and a RR less than 35 bpm. The setting
of NHF was adjusted by the attending physician 1 hour after the
initiation of NHF therapy to achieve SpO2 more than 93% and
respiratory rate less than 30 bpm. Patients were weaned from NHF
therapy by reducing gas flow rate gradually. NHF therapy was considered
successful if the patients were weaned from NHF therapy without
respiratory failure as defined below, rescue NIV therapy, and intubation
for 24 hours.
In the historical control group, the weaning from NIV was performed in
the same way as the NHF therapy group. They received standard face
mask oxygen therapy (flow 30 l/min and FIO2 equal to or less than 0.5)
instead of NHF immediately after the interruption of NIV. After weaning
from NIV, the management of the patient was determined by the
attending physician.
Patients were immediately intubated if any of the following immediate
intubation criteria were present: (1) respiratory or cardiac arrest; (2)
respiratory pauses with loss of consciousness or gasping for air; (3)
uncontrolled agitation; (4) massive aspiration; (5) the inability to remove
respiratory secretions; (6) severe hemodynamic instability unresolved by
fluids and vasoactive agents. If patients developed respiratory failure, the
physician in charge of the patient was allowed to use NIV for rescue
therapy at any time. NIV was delivered through full face mask and
adjusted to keep SpO2 equal to or more than 93% and respiratory rate
less than 30 bpm. Respiratory failure was defined as the presence of at
least one of the following criteria: (1) severe hypoxemia with SpO2 less
than 92% or PaO2 less than 70mmHg at FIO2 of 0.5 or more (2) RR
greater than 35 bpm; (3) respiratory acidosis [arterial pH < 7.3 with
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partial pressure of arterial carbon dioxide (PaCO2) > 50 mm Hg]; (4)
clinical signs of respiratory muscle fatigue such as use of accessory
muscle and paradoxical motion of the abdomen; (5) inability to remove
secretions; (6) severe dyspnea. In case of respiratory failure persisting for
more than 4 hours without improvement after NIV application, patients
were to be strongly considered for intubation.
Demographic data, diagnosis, sequential organ failure assessment
(SOFA) score at ICU admission, and duration of NIV were recorded at
the enrollment of the study. Blood pressure, heart rate, RR and SpO2
were monitored continuously. Blood gases were analyzed every morning
at 7 am, just before the interruption of NIV, 1hour after the initiation of
NHF therapy, and at any time if indicated. In the historical control
group, the last blood gas analysis data before liberation from NIV and the
first data after oxygen mask therapy were extracted from medical
records. Duration of NHF therapy, the rate of rescue NIV therapy and
intubation, the frequency of respiratory failure, and the length of ICU
stay after the first liberation from NIV were also recorded. Furthermore,
each patient was asked which device was more comfortable, NIV with full
face mask or NHF with a wide-bore nasal cannula, after completion of
the study in the NHF group.
Primary end point was the change of respiratory parameters, including
P/F ratio and RR, 1 hour after initiation of NHF or oxygen mask
compared with those during NIV. Secondary end points were the rate of
rescue NIV therapy and intubation, the frequency of respiratory failure,
the duration of NHF therapy, the length of ICU stay after weaning from
NIV, and acceptability of NHF therapy compared with NIV.
Results were presented as mean ±SD for variables with a normal
distribution, or medians and interquartile range for variables with a non-
normal distribution, and compared with Student’s t test or Mann-
Whitney U test as appropriate. Categorical variables were compared with
Fisher’s exact test. A p-value less than 0.05 was considered as
statistically significant.
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Results
All patients under NIV management, who were ready for weaning, were
screened for eligibility over the study period. Nine patients, who passed
the inclusion criteria, participated in the study overall. Clinical
characteristics and demographic data at admission to ICU are
summarized in table1. Duration of NIV ranged from 2 to 6 days. All nine
patients received NHF therapy immediately after interruption of NIV,
and the respiratory setting was not changed until the first blood
sampling, 1 hour after initiation of NHF in all patients.
In the historical control group, who received oxygen mask therapy after
interruption of NIV management, P/F ratio decreased significantly
compared with that just before liberation from NIV therapy (194.3 ± 20.1
versus 255.9 ± 58.1 mmHg, p=0.013; table 2). On the other hand, P/F
ratio did not change significantly in nine patients who received NHF
therapy immediately after weaning from NIV as shown in table 2 (231 ±
43.6 versus 250.7 ± 34.2 mmHg, p=0.367). Respiratory rate after
initiation of NHF or oxygen mask was also comparable with that during
NIV (table 2).
Although two of eight patients in the historical control group required
rescue NIV therapy again due to development of respiratory failure, of
whom one patient was intubated after all, no patient developed
respiratory failure or received NIV rescue therapy after initiation of NHF
therapy in the NHF group. However, there was no significant difference
between both groups regarding the rate of rescue NIV therapy
(p=0.206). The duration of NHF therapy was 2 (1 to 3.25) days, and the
length of ICU stay after liberation from NIV in the NHF group was not
different significantly from that of the historical control group {4 (3 to
5.25) versus 2 (2 to 4) days, p=0.124}. Eight of nine patients who
received NHF therapy after NIV management preferred NHF therapy to
NIV.
Discussion
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Our study demonstrated that NHF therapy after weaning from NIV is
effective in maintaining sufficient oxygenation compared with oxygen
face mask therapy in the historical control group, in which P/F ratio
decreased significantly after liberation from NIV and two patients
received NIV rescue therapy after all. These results suggest that the
weaning strategy from NIV through NHF application may be safe and
effective in terms of that NHF could maintain sufficient oxygenation and
prevent respiratory failure, which develops after liberation from NIV
therapy.
In this study, P/F ratio, representing the oxygenation status, was
maintained in the NHF therapy group after weaning from NIV, while
oxygen face mask therapy could not maintain oxygenation level
compared to CPAP with PEEP level of 4 cmH2O. This result indicates
that minimum PEEP level of 4 cmH2O in NIV device contributes to
oxygenation and NHF with 50 l/min flow rate can generate the same
PEEP level. Previous studies have reported that NHF can produce PEEP
dependent on flow rate, (12) which may improve ventilation perfusion
matching and oxygenation. Although the actual PEEP level generated by
NHF in this study is uncertain, to our knowledge, this is the first study
which examined the effect of NHF on respiratory parameters compared
with CPAP mode of NIV, and showed that 50 l/min flow rate of NHF had
comparable effects on oxygenation with 4 cmH2O PEEP level.
Furthermore, no patients weaned from NIV to NHF in this study
developed respiratory failure or required rescue NIV therapy or
intubation, while two patients in the historical control group required
NIV again due to respiratory failure after weaning from NIV. Although a
further study is warranted, this result implies the effectiveness of the
weaning strategy from NIV management through NHF application.
Recently, data are accumulating which show the beneficial effects of NHF
oxygen therapy not only in premature infants, (13) but also in adult
respiratory failure. (7) In observational studies, NHF application in
hypoxic respiratory failure patients has been reported to improve
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oxygenation, reduce respiratory rate and attenuate respiratory fatigue,
compared to high flow face mask oxygen therapy. (14) A recent small
randomized trial, (15) which included 60 patients not requiring
mechanical ventilator support, with mild to moderate hypoxic
respiratory failure, demonstrated that NHF therapy could reduce the rate
of worsening respiratory failure compared with face mask oxygen
therapy, although P/F ratio wasn’t different significantly between
groups. Another randomized trial, (16) which compared NFH therapy
and high flow face mask therapy, has shown that NHF improved
patient’s tolerance even though there was no significant difference
regarding respiratory parameters. While it remains to be clarified
whether NHF oxygen therapy is actually superior to high flow oxygen
mask therapy in management of respiratory failure, some mechanisms
by which NHF could contribute to improvement of gas exchange should
be considered. PEEP generated by NHF therapy could play a major role
for improvement of oxygenation. The level of PEEP produced by NHF
therapy has been reported to be affected by various factors, such as
whether breathing is with open or closed mouth, (8) patient’s sex, (17)
and delivered flow rate. (12) The PEEP effect delivered by NHF could
contribute to expansion of lung volume through recruitment of
atelectasis, (18) reduction of work of breathing, (19) and improvement of
ventilation-perfusion ratio, leading to improved respiratory condition.
Reduction of dead space is also one of the possible mechanisms for
clinical benefits of NHF. (19) The high flow rate generated by NHF
system could wash-out expired CO2 from the upper airway, which can
reduce rebreathing of CO2 and increase FIO2 which patients actually
inspire. This beneficial effect may be quite outstanding, especially in
hypercapnic respiratory failure such as COPD. Furthermore, NHF is
likely to be better tolerated than face mask, improving patient adherence
to oxygen therapy and treatment effectiveness. (16) Face mask may cause
discomfort through difficulties of oral intake and communication, (20)
which could prevent effective continuous oxygen therapy. In this study,
all patients tolerated NHF well, and almost all of them described NHF as
more comfortable than NIV through full face mask.
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There are several limitations to interpreting the data herein. First, this is
not a randomized controlled trial, but an observational study which
included only nine patients. It is unknown whether an application of
NHF after liberation from NIV management could reduce the frequency
of pulmonary complications, respiratory failure and mechanical
ventilator support, which should be evaluated in large randomized
controlled trials in the future. However, no patients who received NHF
therapy after liberation from NIV required rescue NIV therapy, while two
patients in the historical control group needed rescue NIV. Second, our
results might not be applicable to other type of diseases such as
pneumonia and chronic obstructive pulmonary disease, since almost all
patients were post-cardiovascular surgery patients with cardiac
dysfunction. Finally, we evaluated the effect of NHF with 50 l/min flow
rate on respiratory parameters, compared with CPAP mode with 4
cmH2O PEEP level in this study. Thus, whether NHF therapy would be
comparable with higher PEEP levels is unknown. In the study evaluating
the efficacy of NHF in preterm infants after extubation, NHF therapy has
been reported to have similar efficacy and safety to nasal CPAP with 7
cmH2O PEEP. (21) Further study is warranted to examine the degree of
PEEP level at which patients could wean from NIV to NHF therapy in
adult patients.
Conclusion
In this study, NHF with 50 l/min flow rate was found to have comparable
effects with 4 cmH2O PEEP level of CPAP mode regarding oxygenation,
which suggests NHF might be effective and safe for preventing
respiratory failure after weaning from NIV. Further investigation is
necessary to establish the beneficial effects of NHF after liberation from
NIV management.
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Table 1. Characteristics of nine patients who received NHF therapy after
liberation from NIV.







1 79 F 14.6 Post AVR 8 2 2
2 82 F 29.8 Post AVR 15 6 1
3 83 M 24.5 Post CABG andMVR 8 2 2
4 74 F 19.1 Post AVR 9 2 4
5 84 M 18.1 Post gastrectomy 8 6 3





7 72 F 20.8 Post PCI 7 3 1
8 74 F 29.6 Post CABG 13 2 1
9 70 M 18.3 Post CABG andAVR 11 2 1
AVR, aortic valve replacement; BMI, index; CABG, coronary artery
bypass graft; F, female; M, male;
MVR, mitral valve replacement; NHF, nasal high flow; NIV, non-invasive
ventilation; PCI, percutaneous coronary intervention;
SOFA score, sequential organ failure assessment score.
Table 2. Changes in respiratory parameters after liberation from NIV.




















No Before After Before After Before After Before After
1 204 188.2 22 22 239.6 218.4 22 18
2 291.4 296.2 23 22 306.8 195 20 24
3 287.5 236.5 21 16 245.8 208.4 22 25
4 207.6 211.8 20 20 364.8 207.8 16 19
5 212.6 193.4 20 22 166 152.4 22 26
6 252.6 211.4 18 24 245 188.2 18 20
7 265.3 310 22 22 233.2 186.2 23 26
8 292.5 248.5 20 18 245.8 198.3 24 22





















*: p = 0.013 compared with before
NHF, nasal high flow; NIV, non-invasive ventilation; P/F ratio, partial
pressure of arterial oxygen (PaO2) to fraction of inspiratory oxygen
(FIO2) ratio; RR, respiratory rate.
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